Treatment with CDK4/6 inhibitors has been shown to significantly improve progression-free survival in metastatic ERα-positive breast cancers when prescribed in combination with either letrozole as first-line therapy in endocrine-sensitive disease [20,22,23] or with fulvestrant as second-line therapy in endocrine-resistant tumours [21]. This evidence concerns the gene ESR1 and breast carcinoma.